These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
285 related items for PubMed ID: 20724820
1. Autophagic degradation of an oncoprotein. Bøe SO, Simonsen A. Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820 [Abstract] [Full Text] [Related]
2. Acute promyelocytic leukemia: a paradigm for differentiation therapy. Grimwade D, Mistry AR, Solomon E, Guidez F. Cancer Treat Res; 2010 Oct; 145():219-35. PubMed ID: 20306254 [Abstract] [Full Text] [Related]
9. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology. Zhu G. Curr Pharm Biotechnol; 2013 Oct 15; 14(9):849-58. PubMed ID: 24433507 [Abstract] [Full Text] [Related]
10. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Lo-Coco F, Hasan SK. Best Pract Res Clin Haematol; 2014 Mar 15; 27(1):3-9. PubMed ID: 24907012 [Abstract] [Full Text] [Related]
11. Function of PML-RARA in Acute Promyelocytic Leukemia. Testa U, Pelosi E. Adv Exp Med Biol; 2024 Mar 15; 1459():321-339. PubMed ID: 39017850 [Abstract] [Full Text] [Related]
13. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response. Vitoux D, Nasr R, de The H. Int J Biochem Cell Biol; 2007 Mar 15; 39(6):1063-70. PubMed ID: 17468032 [Abstract] [Full Text] [Related]
14. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells. Guo W, Wang H, Zhao W, Zhu J, Ju B, Wang X. Chin Med J (Engl); 2001 Jan 15; 114(1):30-4. PubMed ID: 11779431 [Abstract] [Full Text] [Related]
15. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. Nasr R, de Thé H. Int J Hematol; 2010 Jun 15; 91(5):742-7. PubMed ID: 20455087 [Abstract] [Full Text] [Related]
16. What is the role of arsenic in newly diagnosed APL? Tallman MS. Best Pract Res Clin Haematol; 2008 Dec 15; 21(4):659-66. PubMed ID: 19041605 [Abstract] [Full Text] [Related]
17. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Zhu J, Lallemand-Breitenbach V, de Thé H. Oncogene; 2001 Oct 29; 20(49):7257-65. PubMed ID: 11704854 [Abstract] [Full Text] [Related]
18. Molecular mechanisms of the antileukemia activities of retinoid and arsenic. Nitto T, Sawaki K. J Pharmacol Sci; 2014 Oct 29; 126(3):179-85. PubMed ID: 25319615 [Abstract] [Full Text] [Related]
19. Acute Promyelocytic Leukemia, Retinoic Acid, and Arsenic: A Tale of Dualities. Rérolle D, Wu HC, de Thé H. Cold Spring Harb Perspect Med; 2024 Sep 03; 14(9):. PubMed ID: 38503502 [Abstract] [Full Text] [Related]
20. A unique case of acute promyelocytic leukemia showing monocytic differentiation after ATRA (all-trans retinoic acid) therapy. Naeem M, Harrison K, Barton K, Nand S, Alkan S. Eur J Haematol; 2006 Feb 03; 76(2):164-6. PubMed ID: 16405439 [Abstract] [Full Text] [Related] Page: [Next] [New Search]